Abstract
Colorectal cancer is a common tumor in the digestive tract with high morbidity and mortality. The products will continue the design of the previous group, PatritumabVedotion. The main treatment target population is HER3-positive colorectal cancer patients who are in stage 3 and stage 4. The antibody selected by our drug is patritumab, which is linked to the cytotoxic drug MMAE through a coupling reaction with MC-Val-Cit-PAB, and the average DAR of this product is expected to be 4. The target market is Europe, and combined with the actual production capacity of the factory, the annual target output is 529.7KG. In addition, two different production modes: fed-batch and Continuous is compared,and the technical and economic is analyzed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
